Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Parkinson’s disease and related disorders

The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.

Gregor K Wenning; Iva Stankovic; Luca Vignatelli; Alessandra Fanciulli; Giovanna Calandra-Buonaura; Klaus Seppi; Jose-Alberto Palma; Wassilios G Meissner; Florian Krismer; Daniela Berg; Pietro Cortelli; Roy Freeman; Glenda Halliday; Günter Höglinger; Anthony Lang; Helen Ling; Irene Litvan; Phillip Low; Yasuo Miki; Jalesh Panicker; Maria Teresa Pellecchia; Niall Quinn; Ryuji Sakakibara; Maria Stamelou; Eduardo Tolosa; Shoji Tsuji; Tom Warner; Werner Poewe; Horacio Kaufmann

Originally published in Movement disorders : official journal of the Movement Disorder Society · 2022-04-21

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology. Methods We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference. Results The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity.

Conclusions

Here we propose new MDS MSA diagnostic criteria that are designed for clinical practice, inclusion of patients in clinical trials, and research studies. The MDS MSA Criteria Revision Task Force aims to conduct a validation exercise on the MDS MSA criteria, including a prospective multicenter clinical study and a clinicopathological study. In particular, validation is needed for the research category of possible prodromal MSA and for supportive biomarkers for MSA diagnosis. We acknowledge that MDS MSA criteria will need revision, as data from ongoing and future studies become available.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?